Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 04 Oct 2024
Health news and commentary gathered by MedPage Today staff
Read Full NewsThe FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.
An analysis of the PROSPECT trial reported that consistent use of transcutaneous afferent patterned stimulation was associated with improvement in underlying tremor severity in patients with essential tremor.
A study of deceased former NFL players estimated that nearly 75% had CTE neuropathology, while a phase 3 trial is evaluating whether F-18 FNT-PET imaging could help identify disease-associated patterns in living patients.
Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.
At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.
Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
1.
VP Nominee Medical Records Breached; Queen Elizabeth's Cancer; Galaxy Gas Whippets
2.
A better option for mild to moderate depression?
3.
Nature Retracts Cancer Study Suggesting Treatment Is Better Earlier in the Day
4.
Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
5.
Two-part prodrug system activates immune attack only in tumor's unique environment
1.
Advanced Directions in Oncology and Quality Improvement
2.
New Anticoagulants: Balancing Efficacy and Safety in Patients with Atrial Fibrillation
3.
Real-World Evidence and Patient Voices: Redefining Outcomes in Modern Oncology
4.
Altered Marrow Cell-Production Dynamics During Chronic Hematologic Stress
5.
Tumor Dormancy Dynamics and Recurrence-Free Survival Patterns
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Cancer Staging Education Through Interactive Anatomical Spread Maps
2.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
5.
Navigating the Complexities of Ph Negative ALL - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge